SRPT outlines 2026 priorities
Sarepta Therapeutics is in a solid cash position and has outlined its priorities for 2026, potentially impacting its stock performance. The company's plans may influence investor decisions.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.